Antiretroviral treatment changes in adults from Côte d'Ivoire: the roles of tuberculosis and pregnancy
Messou, Eugènea,b; Anglaret, Xaviera; Duvignac, Juliena; Konan-N'Dri, Ericb; Komena, Ericb; Gnokoro, Joachimb; Karcher, Sophiea; Tanoh, Anthonyc,d; N'Dri-Yoman, Thérèseb; Seyler, Catherinea
aINSERM U897, Université Victor Segalen Bordeaux 2, Bordeaux, France
bAssociation Aconda, Abidjan, Republic of Côte d'Ivoire, USA
cElizabeth Glaser Pediatric AIDS Foundation, Abidjan, Republic of Côte d'Ivoire, USA
dElizabeth Glaser Pediatric AIDS Foundation, Los Angeles, California, USA.
Received 10 October, 2008
Revised 17 May, 2009
Accepted 29 May, 2009
Correspondence to Xavier Anglaret, MD, PhD, INSERM U897, Université Victor Segalen Bordeaux 2, 146 rue Léo Saignat, 33076 Bordeaux cedex, France. E-mail: Xavier.Anglaret@isped.u-bordeaux2.fr
Objective: To determine the rates and causes of first antiretroviral treatment changes in HIV-infected adults in Côte d'Ivoire.
Methods: We evaluated adults who initiated antiretroviral treatment in an outpatient clinic in Abidjan. We recorded baseline and follow-up data, including drug prescriptions and reasons for changing to alternative first-line regimens (drug substitution for any reason but failure) or second-line regimens (switch for failure).
Results: Two thousand and twelve HIV-infected adults (73% women) initiated antiretroviral treatment. At baseline, 9% of all patients were on treatment for tuberculosis and 3% of women were pregnant. First-line antiretroviral treatment consisted of two nucleoside reverse transcriptase inhibitors (58% stavudine–lamivudine, 42% zidovudine–lamivudine) and efavirenz (63%), nevirapine (32%) or indinavir (5%). Median follow-up time was 16.9 months. During this time, 205 (10%) patients died and 261 (13%) were lost to follow-up. Overall, the rate of treatment modifications was 20.7/100 patient-years. The most common modifications were drug substitutions for intolerance (12.4/100 patient-years), pregnancy (4.5/100 patient-years) and tuberculosis (2.5/100 patient-years). The rates of intolerance-related substitutions were 17.9/100 patient-years for stavudine, 6.3/100 patient-years for nevirapine, 3.9/100 patient-years for zidovudine and 0.1/100 patient-years for efavirenz. Twenty percent of efavirenz substitutions resulted from pregnancy and 18% of nevirapine substitutions were related to tuberculosis treatment.
Conclusion: During the first months following antiretroviral treatment initiation, a third of all treatment changes occurred for reasons other than intolerance to the drug or treatment failure. In Africa, drug forecasting is crucial to ensuring the success of HIV treatment programmes. Drugs that do not require interruptions during pregnancy or tuberculosis treatment should be made more readily available as first-line drugs in sub-Saharan Africa.
In 2007, the World Health Organization (WHO) estimated that 480 000 adults and children were living with HIV in Côte d'Ivoire. Of these HIV-infected individuals, 190 000 persons were estimated to be in need of antiretroviral treatment (ART), of whom only 51 812 (28%) were actually receiving ART [1,2]. As the number of patients starting ART in Côte d'Ivoire continues to rise, numerous medical and logistical challenges have arisen, at both the individual and national levels.
In order for an HIV treatment programme to be successful, appropriate drugs need to be available in sufficient quantity. Three indicators are essential for the maintenance of drug supplies: rate of treatment initiation among ART-naive patients, rate of retention in care and rate of treatment modifications. Although in recent years an increasing number of publications have reported on the number of patients starting ART and remaining in care in large sub-Saharan African programmes [3–7], studies on the rates of ART regimen modifications and their causes have remained scarce [8,9].
Here we report the frequency and causes of first-time ART modifications in a cohort of HIV-infected adults who were followed up for 2.5 years after starting ART in a large HIV care clinic in Abidjan, Côte d'Ivoire.
Setting and patients
In 2003, health professionals from the ANRS/Ministry of Health research programme in Côte d'Ivoire established Aconda, a local nonprofit organization in Abidjan. In June 2004, Aconda launched a 5-year programme in partnership with the Institute of Public Health, Epidemiology and Development (ISPED, Bordeaux, France) to scale up access to HIV care and treatment. This programme was funded by the United States President's Emergency Plan for AIDS Relief (PEPFAR), through the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF, Washington, DC, USA).
Here we present data on adults who started ART between June 2004 and November 2006 in the Centre de Prise en Charge et de Formation (CePReF) clinic, Aconda's largest HIV outpatient clinic. The CePReF clinic is located in Yopougon, a low-income suburb of Abidjan, the economic capital of Côte d'Ivoire.
Standardized follow-up procedures
Follow-up procedures for patients on ART in the Aconda programme have been described elsewhere [3,10]. Clinical, immunologic and biochemical evaluations (serum creatinine and transaminases) were completed before ART initiation. Patients initiated ART according to 2003 WHO criteria: clinical stage 4, CD4 cell count less than 200/μl, or clinical stage 3 and CD4 cell count 200–350/μl. The Aconda programme provided antiretroviral drugs to patients monthly. CD4 cell counts, blood cell counts, serum creatinine and transaminases were measured every 6 months. Plasma HIV viral load and lactate measurements were not routinely available. Patients paid a fixed rate of US$2 per month for antiretroviral drugs and biological tests, which were made available for their entire immediate family. Support groups were organized to encourage patients to adhere to therapy and a community-based team systematically called or made home visits to patients who did not show up to receive the month's antiretroviral drugs. Cotrimoxazole prophylaxis was prescribed for all patients with CD4 cell count less than 500/μl . Isoniazid (INH) prophylaxis was not included in the national treatment protocol and therefore was not prescribed.
The Aconda programme used WHO-recommended first-line antiretroviral drugs. When patients were HIV-1-infected, first-line ART consisted of two nucleoside reverse transcriptase inhibitors (NRTIs) and one non-nucleoside reverse transcriptase inhibitor (NNRTI). When patients were HIV-2-infected or had dual HIV-1 and HIV-2 infections, first-line consisted of two NRTIs and one protease inhibitor. Stavudine (d4T) dosages (30 or 40 mg twice a day) were adapted for patient weight (< or >60 kg) in accordance with WHO recommendations at the date of the study . Women of child-bearing age who initiated regimens containing efavirenz (EFV) were prescribed hormonal contraception. Antituberculosis drugs were prescribed providing standardized criteria for active tuberculosis, as defined at the national level. The standard antituberculosis treatment consists of an intensive phase of 2 months daily rifampicin, isoniazid, pyrazinamide and ethambutol, followed by a continuation phase of 4 months daily isoniazid and rifampicin. Patients on nevirapine who started with a rifampicin-based treatment were switched to EFV.
Patient contact with the study centre, drug deliveries and biological test results were recorded anonymously in an electronic database . Before modifying a patient's ART regimen, physicians filled out a standardized form in which they noted the reason for modification. When intolerance was the reason for substituting drugs, adverse effects were scored according to the AIDS Clinical Trial Group's (ACTG) grading table . Antiretroviral drugs were substituted according to standardized procedures. Single-drug substitutions were recommended whenever possible, except when the cause for regimen modification was ART failure. ART failure was defined based on the WHO criteria for CD4 cell failure (fall of CD4 cell count to pretherapy baseline; or 50% fall from the on-treatment peak value; or persistent CD4 levels below 100 cells/μl) and/or the WHO criteria for clinical failure (new/recurrent WHO stage 4 condition) after 12 months of treatment . Patients who failed a NNRTI-based first-line regimen with zidovudine or stavudine and lamivudine were given abacavir–didanosine–lopinavir/ritonavir as second-line regimen.
The Aconda computerized data management system has been previously described, and has been approved by the National Ethics Committee of Côte d'Ivoire .
The primary outcome was first-time ART modification after treatment initiation. ART modifications included changing treatment to alternative first-line regimens (drug substitution for any reason but failure) or second-line regimens (switch for failure). Baseline was defined as the date of ART initiation. Data were censored on 30 November 2006 for patients who were alive and actively in care, on the date of death for patients who died before 30 November 2006, and on the date of last contact with the care centre for patients who were not known to be dead (transferred out or lost to follow-up) and whose last contact was before 30 November 2006. Patients were defined to be lost to follow-up when their last contact with the study team was more than 3 months on 30 November 2006 and if they were not known to be dead or to have transferred out.
Rates of treatment modifications were calculated per 100 patient-years with 95% confidence intervals (CIs). We used the Kaplan–Meier method to estimate the probability of treatment modifications over time, both overall, by drug and by regimen. We used univariate and multivariate Cox proportional hazard regression models for first events to analyse the association between treatment modification and the following characteristics: sex, age, WHO clinical stage, haemoglobin, creatinine or transaminase level, body mass index (BMI) and CD4 cell count and ART regimen at ART initiation; and history of tuberculosis before ART initiation, prevalence of tuberculosis at ART initiation and incidence of tuberculosis during follow-up after ART initiation. Sex, age, haemoglobin, CD4 cell count, BMI and tuberculosis were a priori decided to be included in multivariate analysis regardless of their association with the outcome in univariate analysis. The variables were checked for multicollinearity by examining Tolerance and the Variance Inflation Factor. Analyses were run using SAS software, version 9.1 (SAS Institute inc., Cary, North Carolina, USA).
Role of the funding source
The sponsors of the treatment programme (PEPFAR, EGPAF and Côte d'Ivoire Ministry of Public Health) had no role in the study design, data collection, data analysis, interpretations of data or writing of the report.
Between 1 June 2004 and 30 November 2006, 2012 ART-naive HIV-infected adults (73% women) initiated ART in the CePReF clinic, including 1887 (93.8%) HIV-1-infected patients, 77 (3.8%) HIV-2-infected patients, 36 (1.8%) HIV-1-infected and HIV-2-infected patients and 12 (0.6%) patients with no HIV subtyping available. At baseline, median pre-ART CD4 cell count was 125/μl, 208 patients (10%) had a self-reported history of active tuberculosis and 182 (9%) had active disease with tuberculosis. The other main characteristics are detailed in Table 1.
Of the 2012 patients evaluated, 1902 (94.5%) initiated ART with two NRTIs and one NNRTI. Of these, 639 (34%) were given a fixed-dose combination of stavudine–lamivudine–nevirapine (Triomune; Cipla Ltd, India,), 759 (40%) were given a fixed-dose combination of zidovudine–lamivudine (Duovir; Cipla Ltd), with EFV (Aurobindo Pharma), 502 (26%) were given a combination of stavudine–lamivudine (Lamivir; Cipla Ltd) with EFV (Aurobindo Pharma), one was given fixed-dose combination of zidovudine–lamivudine (Duovir; Cipla Ltd) with nevirapine (Aurobindo Pharma), and one was given abacavir (Aurobindo Pharma) and didanosine (Aurobindo Pharma), and EFV (Aurobindo Pharma). These drugs were delivered under the PEPFAR programme or the Global Fund to Fight AIDS, Tuberculosis and Malaria. Overall, 1170 (58%) patients initiated ART with a d4T-containing regimen.
Patients were followed up for a median of 16.9 months [interquartile range (IQR) 9.2–22.8] after ART initiation. By the end of the study, 1424 (71%) patients were alive and actively being followed up, 205 (10%) were known to be dead, 122 (6%) had transferred out and 261 (13%) were lost to follow-up. Median time to death was 2.5 months (IQR 0.9–6.1) and median time to loss to follow-up was 8.2 months (IQR 4.1–11.3).
Overall, 483 (24%) patients had a treatment change, at a rate of 20.7/100 patient-years (95% CI 18.9–22.7) for the first change. Table 2 shows the rates and causes of treatment modifications by initial ART regimen for the three most commonly prescribed regimens. The highest rate of first-time treatment modification was found among patients initiating treatment with a fixed-dose combination of stavudine–lamivudine–nevirapine. Rates of treatment modification were close among patients initiating treatment with stavudine–lamivudine–EFV and much lower among patients initiating treatment with zidovudine–lamivudine–EFV.
Pregnancy-related substitution of nevirapine for EFV accounted for 12.2% of overall treatment modifications, 19.6% of modifications among patients taking EFV, and 23.5% of modifications among women taking EFV. The rate of treatment modification due to pregnancy in the overall population was 4.5/100 patient-years (95% CI 3.7–5.3). Switches from nevirapine to EFV related to the initiation of a rifampicin-based antituberculosis treatment accounted for 6% of overall treatment modifications and 18% of treatment modifications among patients on nevirapine. The rate of ART modification due to the initiation of a rifampicin-based antituberculosis treatment in the overall population was 2.5/100 patient-years (95% CI 1.9–3.1). Intolerance was the main cause of treatment modification, with an incidence of 12.4/100 patient-years (95% CI 11–13.8) in the overall population. Rates of modification for each drug are shown in Table 3. The rates of intolerance-related drug substitutions were very low for EFV (0.1/100 patient-years), low for zidovudine (3.9/100 patient-years), intermediate for nevirapine (6.3/100 patient-years) and very high for stavudine (17.9/100 patient-years). As shown in Table 3 and Fig. 1, most intolerance-related drug substitutions occurred during the first few months of treatment, with the exception of stavudine substitutions, which increased steadily over the entire study period.
As shown in Table 1, drug stock-outs were a non-negligible cause of treatment modification. Patients were sometimes forced to change treatment in order to avoid treatment interruptions. Although stock-outs accounted for only 1% of stavudine–lamivudine–nevirapine modifications, they represented 5–6% of modifications for other regimens.
The factors associated with intolerance-related treatment modifications are shown in Table 4. Neither the tolerance values (all >0.2) nor the Variance Inflation Factor statistics (all <4) indicated a problem of multicollinearity for any of the variables in the multivariate analysis. In multivariate analysis, d4T substitutions due to intolerance (mainly, peripheral neuropathy) were significantly associated with age. We did not find a significant association between d4T substitution and previous or ongoing antituberculosis treatment. Substitution of zidovudine was strongly associated with baseline haemoglobin and baseline antituberculosis treatment. We did not find significant associations between nevirapine substitution and any of the baseline or follow-up patient characteristics.
We report here on the incidence, risk factors and causes of first-line ART regimen modifications in 2012 HIV-infected adults who were followed for a median of 17 months after ART initiation during the first 2 years of an ART roll-out programme in Côte d'Ivoire.
As expected, regimen switches due to failure were rare during the early phase of ART and treatment modifications were mainly due to intolerance. However, we also found that a third of regimen modifications were related not to intolerance or treatment failure, but rather to pregnancies and tuberculosis, which frequently led to EFV and nevirapine substitutions, respectively.
Non-nucleoside reverse transcriptase inhibitors are essential to first-line ART regimens in sub-Saharan Africa. When nevirapine and EFV are available, physicians must decide which drug to prescribe, based on the cost of the drug, the risk of intolerance to the drug, the existence of a fixed-combination pill and the patient's pre-ART characteristics. In settings with a substantial prevalence of tuberculosis and proportion of HIV-infected women of child-bearing age, both nevirapine and EFV have a high likelihood of being substituted for the other for reasons other than intolerance. On the contrary, although ART does reduce the incidence of tuberculosis, it remains the leading severe opportunistic infection during the first years on ART . Some studies have explored the possibility of using nevirapine and rifampicin concomitantly , but both WHO guidelines and government directives in countries like Côte d'Ivoire still recommend the substitution of EFV for nevirapine during rifampicin therapy . On the contrary, EFV has a potential embryo/foetotoxicity. Prescribing contraceptives in women taking EFV is only part of the solution, as various studies have shown that the rate of pregnancy in women taking contraceptives remains significant [17,18]. In additions, pregnancy rates in women taking ART will likely increase in the future, as ART helps CD4 cell counts rise .
The clinical consequences of switching from one NNRTI to another are likely to be limited at the individual level and under good conditions of care, but they still deserve to be studied in settings in which resources for managing intolerance and nonadherence are limited. Furthermore, high rates of nevirapine and EFV cross-over may hinder drug forecasting at the programme level. In sub-Saharan Africa, drug forecasting and stable drug management systems are crucial to ensuring the success of HIV treatment programmes ; reductions in rates of drug switches could contribute to the success of ART delivery programmes.
So far, only a handful of articles have reported on the rates and causes of first-time ART regimen modifications due to intolerance in sub-Saharan Africa [8,17,21]. These studies all focused on treatment modification, and not drug toxicity. Though the rate of intolerance-related treatment modification does likely reflect the rate of severe toxicity events, it only acts as an imperfect proxy. In our setting, fatal toxicity may remain undiagnosed, with patients dying or withdrawing from care before switching drugs. Furthermore, limited access to care, and second-line ART, as well as infrequent diagnoses of side effects, curtail the patient's ability to switch drugs , perhaps explaining the relatively low rates of treatment modification we report, compared to those reported in developed countries [22–25]. Finally, in our study 13% of patients were lost to follow-up and were censored at the date of last contact with the centre. This censoring could be informative, thus leading us to misestimate the rate of severe drug toxicity and/or the rate of treatment failure.
Within the limitations stated above, the rates of toxicity and times to regimen modification reported here are consistent with those previously reported in sub-Saharan African countries [8,17,21]. As expected, stavudine was associated with the highest rate of and longest time to regimen modification. In our context, the diagnosis of lactic acidosis is rarely made . The most common causes of stavudine discontinuation in routine care are lipodystrophy and peripheral neuropathy. Although over-diagnosis of these adverse events may have occurred in our study, some patients who were intolerant to stavudine may not have substituted the drug because they did not have easy access to the healthcare facility, or second-line drugs were not available. As expected, intolerance-related drug discontinuations were much lower for EFV and zidovudine, compared with nevirapine and stavudine, respectively.
Low pre-ART CD4 cell count and older age were significantly associated with stavudine-containing regimen modifications and pre-ART anaemia was associated with zidovudine-containing regimen modifications [27,28]. The design of the study, sample size and limited number of variables, however, do limit our interpretation of the factors associated with toxicity-related regimen modifications. Some key variables such as prevalence of hepatitis B virus co-infection are missing and may have acted as confounding factors .
In conclusion, we have found evidence that rates of both pregnancy-related EFV discontinuations and tuberculosis-related nevirapine discontinuations are high in this population of West-African adults, in which the proportion of women is large and for which both drugs are equally available. In addition, we found that a remarkably low rate of EFV discontinuations was associated with drug intolerance. Rates of ART regimen modifications in patients taking EFV and any NRTI except for stavudine would be strikingly low if EFV was shown to be well tolerated for pregnant women. If new data are not reported soon supporting the use of EFV during pregnancy or the use of nevirapine during tuberculosis treatment, the dilemma between these two NNRTIs will persist. Instead, other newer drugs that do not require interruptions during tuberculosis or pregnancy will have to be made more readily available as first-line drugs in sub-Saharan Africa.
List of the Centre de Prise en Charge et de Formation (CePReF) health workers: Pierre Aka, Amani Anzian, Nicole Dakoury-Dogbo, Mamadou Diarrassouba, Lambert Konan, Sidonie Dohoun-Kosseassé, Eric Konan-N'Dri, Joachim Gnokoro, Jeanot Goli, Patrick Gouessé, Marie-Cécile Kassi, Agnès Kati, Eric Komena, Lucie Konan, Michel Konan, Georgette Labibi, Eugène Messou, Yves Mobio, Denis Niamien, Marie-Pascale Nogbou, Abou Sorho, Adidiata Soro, Amah Tchehy, Landry Yepié, Agnès Yoman, Zamblé-Bi.
Participants in the study were treated in a programme funded by the Côte d'Ivoire Ministry of Public Health and the United States President's Emergency Plan for AIDS Relief (PEPFAR), through the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF, Washington DC, USA), The study was funded by the French National Agency for research on AIDS and viral hepatitis (ANRS, France, grant 1203).
3. Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, Duvignac J, et al. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cote d'Ivoire: 2-year outcomes and determinants. AIDS 2008; 22:873–882.
4. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006; 296:782–793.
5. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006; 367:1335–1342.
6. Fairall LR, Bachmann MO, Louwagie GM, van Vuuren C, Chikobvu P, Steyn D, et al. Effectiveness of antiretroviral treatment in a South African program: a cohort study. Arch Intern Med 2008; 168:86–93.
7. Wester CW, Kim S, Bussmann H, Avalos A, Ndwapi N, Peter TF, et al. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr 2005; 40:336–343.
8. Boulle A, Orrel C, Kaplan R, Van Cutsem G, McNally M, Hilderbrand K, et al. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther 2007; 12:753–760.
9. Forna F, Liechty CA, Solberg P, Asiimwe F, Were W, Mermin J, et al. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2007; 44:456–462.
10. Seyler C, Adje-Toure C, Messou E, Dakoury-Dogbo N, Rouet F, Gabillard D, et al. Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa. AIDS 2007; 21:1157–1164.
11. Anglaret X, Messou E, Ouassa T, Toure S, Dakoury-Dogbo N, Combe P, et al. Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Cote d'Ivoire. AIDS 2003; 17:575–584.
13. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm Rep 2002; 51:1–55.
14. Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 2007; 21:2483–2491.
15. Manosuthi W, Ruxrungtham K, Likanonsakul S, Prasithsirikul W, Inthong Y, Phoorisri T, et al. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. Clin Infect Dis 2007; 44:141–144.
17. Danel C, Moh R, Anzian A, Abo Y, Chenal H, Guehi C, et al. Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa. J Acquir Immune Defic Syndr 2006; 42:29–35.
18. Bussmann H, Wester CW, Wester CN, Lekoko B, Okezie O, Thomas AM, et al. Pregnancy rates and birth outcomes among women on efavirenz-containing highly active antiretroviral therapy in Botswana. J Acquir Immune Defic Syndr 2007; 45:269–273.
19. Loko MA, Toure S, Dakoury-Dogbo N, Gabillard D, Leroy V, Anglaret X. Decreasing incidence of pregnancy by decreasing CD4 cell count in HIV-infected women in Cote d'Ivoire: a 7-year cohort study. AIDS 2005; 19:443–445.
20. Harries AD, Schouten EJ, Makombe SD, Libamba E, Neufville HN, Some E, et al. Ensuring uninterrupted supplies of antiretroviral drugs in resource-poor settings: an example from Malawi. Bull World Health Organ 2007; 85:152–155.
21. Tonwe-Gold B, Ekouevi DK, Viho I, Amani-Bosse C, Toure S, Coffie PA, et al. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. PLoS Med 2007; 4:e257.
22. d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000; 14:499–507.
23. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Lepri AC, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001; 15:185–194.
24. Kirk O, Gerstoft J, Pedersen C, Nielsen H, Obel N, Katzenstein TL, et al. Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort. HIV Med 2001; 2:43–51.
25. Smith CJ, Sabin CA, Lampe FC, Shah S, Tyrer M, Youle MS, et al. The relationship between CD4 cell count nadirs and the toxicity profiles of antiretroviral regimens. Antivir Ther 2005; 10:459–467.
26. Mutimura E, Stewart A, Rheeder P, Crowther NJ. Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 46:451–455.
27. Lichtenstein KA, Armon C, Baron A, Moorman AC, Wood KC, Holmberg SD. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis 2005; 40:148–157.
28. Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A, et al. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d'Ivoire. Antivir Ther 2005; 10:615–624.
29. Dieterich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis 2004; 38(Suppl 2):S80–89.
adults; antiretroviral treatment; efavirenz; modification; nevirapine; pregnancy; sub-Saharan Africa; tolerance; tuberculosis
© 2010 Lippincott Williams & Wilkins, Inc.
Highlight selected keywords in the article text.